Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment

被引:56
作者
Clark, LH [1 ]
Setzer, RW [1 ]
Barton, HA [1 ]
机构
[1] US EPA, Off Res & Dev, Natl Hlth & Environm Effects Res Lab, Expt Toxicol Div, Res Triangle Pk, NC 27711 USA
关键词
model evaluation; PBPK models; pharmacokinetics; risk assessment;
D O I
10.1111/j.0272-4332.2004.00561.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Proposed applications of increasingly sophisticated biologically-based computational models, such as physiologically-based pharmacokinetic models, raise the issue of how to evaluate whether the models are adequate for proposed uses, including safety or risk assessment. A six-step process for model evaluation is described. It relies on multidisciplinary expertise to address the biological, toxicological, mathematical, statistical, and risk assessment aspects of the modeling and its application. The first step is to have a clear definition of the purpose(s) of the model in the particular assessment; this provides critical perspectives on all subsequent steps. The second step is to evaluate the biological characterization described by the model structure based on the intended uses of the model and available information on the compound being modeled or related compounds. The next two steps review the mathematical equations used to describe the biology and their implementation in an appropriate computer program. At this point, the values selected for the model parameters (i.e., model calibration) must be evaluated. Thus, the fifth step is a combination of evaluating the model parameterization and calibration against data and evaluating the uncertainty in the model outputs. The final step is to evaluate specialized analyses that were done using the model, such as modeling of population distributions of parameters leading to population estimates for model outcomes or inclusion of early pharmacodynamic events. The process also helps to define the kinds of documentation that would be needed for a model to facilitate its evaluation and implementation.
引用
收藏
页码:1697 / 1717
页数:21
相关论文
共 97 条
[1]   Physiologically based pharmacokinetic models for the transport of trichloroethylene in adipose tissue [J].
Albanese, RA ;
Banks, HT ;
Evans, MV ;
Potter, LK .
BULLETIN OF MATHEMATICAL BIOLOGY, 2002, 64 (01) :97-131
[2]   Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform [J].
Allen, BC ;
Covington, TR ;
Clewell, HJ .
TOXICOLOGY, 1996, 111 (1-3) :289-303
[3]   A multicompartment geometric model of the liver in relation to regional induction of cytochrome P450s [J].
Andersen, ME ;
Eklund, CR ;
Mills, JJ ;
Barton, HA ;
Birnbaum, LS .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1997, 144 (01) :135-144
[4]   PHYSIOLOGICALLY BASED PHARMACOKINETICS AND THE RISK ASSESSMENT PROCESS FOR METHYLENE-CHLORIDE [J].
ANDERSEN, ME ;
CLEWELL, HJ ;
GARGAS, ML ;
SMITH, FA ;
REITZ, RH .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1987, 87 (02) :185-205
[5]   Regional hepatic CYP1A1 and CYP1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin evaluated with a multicompartment geometric model of hepatic zonation [J].
Andersen, ME ;
Birnbaum, LS ;
Barton, HA ;
Eklund, CR .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1997, 144 (01) :145-155
[6]   APPLYING SIMULATION MODELING TO PROBLEMS IN TOXICOLOGY AND RISK ASSESSMENT - A SHORT PERSPECTIVE [J].
ANDERSEN, ME ;
CLEWELL, HJ ;
FREDERICK, CB .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1995, 133 (02) :181-187
[7]   QUANTITATIVE-EVALUATION OF THE METABOLIC INTERACTIONS BETWEEN TRICHLOROETHYLENE AND 1,1-DICHLOROETHYLENE INVIVO USING GAS UPTAKE METHODS [J].
ANDERSEN, ME ;
GARGAS, ML ;
CLEWELL, HJ ;
SEVERYN, KM .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1987, 89 (02) :149-157
[8]  
Andersen ME, 1999, NEUROTOXICOLOGY, V20, P161
[10]   Evaluating noncancer effects of trichloroethylene: Dosimetry, mode of action, and risk assessment [J].
Barton, HA ;
Clewell, HJ .
ENVIRONMENTAL HEALTH PERSPECTIVES, 2000, 108 :323-334